



Sleep Disturbances as a Risk Factor for Stroke

Dae Lim Koo,^a Hyunwoo Nam,^a Robert J. Thomas,^b Chang-Ho Yun^c

^aDepartment of Neurology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea

^bDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA

^cDepartment of Neurology, Bundang Clinical Neuroscience Institute, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

Sleep, a vital process of human being, is carefully orchestrated by the brain and consists of cyclic transitions between rapid eye movement (REM) and non-REM (NREM) sleep. Autonomic tranquility during NREM sleep is characterized by vagal dominance and stable breathing, providing an opportunity for the cardiovascular-neural axis to restore homeostasis, in response to use, distress or fatigue inflicted during wakefulness. Abrupt irregular swings in sympathovagal balance during REM sleep act as phasic loads on the resting cardiovascular system. Any causes of sleep curtailment or fragmentation such as sleep restriction, sleep apnea, insomnia, periodic limb movements during sleep, and shift work, not only impair cardiovascular restoration but also impose a stress on the cardiovascular system. Sleep disturbances have been reported to play a role in the development of stroke and other cardiovascular disorders. This review aims to provide updated information on the role of abnormal sleep in the development of stroke, to discuss the implications of recent research findings, and to help both stroke clinicians and researchers understand the importance of identification and management of sleep pathology for stroke prevention and care.

Correspondence: Chang-Ho Yun
Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea
Tel: +82-31-787-7469
Fax: +82-31-787-4059
E-mail: ych333@gmail.com

Received: December 13, 2017
Revised: January 7, 2018
Accepted: January 15, 2018

Keywords: Sleep initiation and maintenance disorders; Sleep; Sleep apnea syndromes; Stroke; Cardiovascular system; Homeostasis

Introduction

Stroke incidence and early stroke mortality have been decreasing, at least in developed countries, although stroke remains one of leading causes of death and significant disability worldwide.¹⁻⁵ Identification and active modification of risk factors, as well as progress in acute stroke care, underlie the improvements in stroke statistics. Modifiable risk factors such as high blood pressure, hyperlipidemia, diabetes, smoking, physical inactivity, and unhealthy diet are responsible for 90% of the risk

of stroke.^{6,7} However stroke incidence has not dropped significantly in young adults, and is still soaring in low and middle income countries.^{2,3,8} The absolute numbers of stroke victims and resulting deaths, and the associated societal burden are great and even increasing.² Insufficient modification of the established risk factors, or the ongoing effects of under-recognized risks, might explain the high global burden of stroke. Recently, the role of sleep pathology in the development of cardiovascular and metabolic diseases has been highlighted by experimental and observational studies.⁹⁻¹⁵

Sleep is an indispensable part of life, as with feeding and reproduction, all animal species require sleep. Humans sleep almost one-third of their lifetime, which is similar in industrialized and in pre-industrial societies.^{16,17} Sleep, although characterized by quiescence and diminished responsiveness, is not a simple state of rest, but rather a cyclic state of periodic transitions between rapid-eye-movement (REM) and non-REM (NREM) sleep, which are precisely regulated by the central nervous system.¹⁸ Along with the brain and other organs or physiological streams, the cardiovascular system achieves homeostatic restoration during sleep, mainly through autonomic circulatory control.¹⁹ For example, the decrease in blood pressure during sleep, "dipping," is a key biomarker of cardiovascular health, secondary to changes in activity and posture and also under the influence of sleep and circadian rhythms.^{20,21} During NREM sleep, the largest portion (up to 80%) of normal adult sleep, the autonomic system is stabilized with vagal dominance, reduced sympathetic tone, and heightened baroreceptor gain, contributing to a significant reduction in blood pressure and heart rate, with the greatest drop occurring during slow wave sleep.²¹⁻²⁴ This salutatory milieu makes it easy for the cardiovascular system to maintain homeostasis. In contrast, REM sleep—occupying about 20% of total sleep—is dominated by marked fluctuations in sympathovagal balance (irregularly peaking sympathetic surges against a background of tonic vagal inhibition), which lead to abrupt changes in blood pressure and heart rate.^{9,19,22,24} A compromised cardiovascular system is at risk for pathological events such as myocardial ischemia or arrhythmias during REM sleep. Sleep thus acts as a gatekeeper through cyclic oscillations between NREM and REM sleep, switching between autonomic tranquility and turmoil.

Any causes of sleep curtailment, including sleep restriction, insomnia, and shift work, are likely to impair cardiovascular restoration through a reduction in cardioprotective stable NREM sleep. Sleep fragmentation, conventionally defined by cortical EEG arousals, is a universal feature of almost all sleep disorders, including sleep apnea, insomnia, periodic limb movements during sleep (PLMS) and narcolepsy, and is associated with overshoots in sympathetic activity.^{25,26} Even if REM sleep is preserved, the greater the sleep fragmentation, the farther the sympathovagal modulation is tilted toward sympathetic dominance.²⁷ Blood pressure regulation during the biological night (the usual sleep time) is uniquely related to cardiovascular risk, including the risk of stroke.²⁸⁻³⁰ Non-dipping—loss of the typical blood pressure drop during sleep—is associated with a host of poor cardiac, neurological, metabolic, and renal outcomes.³¹⁻³⁶ Sleep fragmentation causes non-dipping.³⁷⁻⁴⁰ Non-dipping is common in older adults and is associated with an

increased risk of stroke.⁴¹⁻⁴³ Reduced dipping is associated with brain atrophy, worse functional status, and lower daytime cerebral blood flow.^{44,45}

The deleterious effects of sleep disturbances go far beyond autonomic circulatory derangement. Common sleep disorders such as sleep apnea, insomnia, and PLMS activate multiple mechanisms including intermittent hypoxia-reoxygenation injury, inflammation, insulin resistance, hypothalamic-pituitary-adrenal axis activation, hemodynamic swings, cardiac arrhythmia, and hypercoagulability, all of which have the potential to provoke cardiovascular diseases (Figure 1).^{9,46}

However, compared with studies on well-established risk factors, research on the role of sleep pathology in the development of cardiovascular diseases, including stroke, has largely been observational or experimental.^{13,47-58} To complicate matters, recent randomized trials have failed to determine the beneficial effect of positive airway pressure therapy in the secondary prevention of cardiovascular events or mortality in sleep apnea.⁵⁹⁻⁶¹ However, serious flaws are pervasive in these studies, including poor use of therapy. This review aims to (1) provide an update of the available information regarding the role of sleep disturbances on the development of stroke; (2) discuss the implications of recent clinical trials and observational studies; and (3) help both stroke clinicians and researchers understand the importance of identification and management of sleep pathology for primary prevention in the general and stroke-prone populations, and for the care of acute and chronic stroke.

Obstructive sleep apnea

Obstructive sleep apnea (OSA) is characterized by repetitive cessations or reductions in airflow caused by complete or partial upper airway collapse (Figure 2). The prevalence of moderate-to-severe OSA in the adult general population is 9% to 14% in men and 4% to 7% in women,⁶²⁻⁶⁵ increasing with age,⁶⁶ and even higher in a recent study (49.7% in men, 23.4% in women).⁶⁷ Measurement methods and scoring criteria heavily impact reported prevalence rates. Nevertheless, the prevalence and incidence of OSA is clearly increasing, driven by the aging of societies and the obesity epidemic.⁶⁸ Four decades after a report on the high prevalence of hypertension in pediatric and adult OSA,⁶⁹ numerous experimental and observational studies have provided evidence that OSA promotes the development of cardiovascular diseases, including stroke.^{9,12,46,70}

Links between OSA and stroke

OSA creates a substrate for stroke vulnerability, and is particu-




Figure 1. The mechanisms of sleep disturbances contributing to the development of stroke. PLMS, periodic limb movements during sleep; RLS, restless legs syndrome.




Figure 2. Snapshot of recurrent respiratory events in obstructive sleep apnea. (A) Electroencephalography (EEG) plots for 30-second epoch. Respiratory arousal (closed arrowhead in panel A) occurs at the end of obstructive sleep apnea (closed arrowhead in panel B) in stage 2 rapid-eye-movement (REM) and non-REM sleep. The closed arrowheads on panel A and B indicate the same time. (B) Respiratory plots for three-minute epoch. Repetitive cessations of airflow (closed arrows) despite ongoing respiratory movements of the chest and abdominal belt are typical features. Obstructive sleep apnea is accompanied by decreased oxygen saturation (open arrows) and increased heart rate (open arrowheads). L, left; R, right; EOG, electrooculography; EMG, electromyography; EKG, electrocardiogram; SpO₂, peripheral oxygen saturation.

larly hostile to brain function. Exposure to intermittent hypoxia in rodents results in impaired executive function, excessive sleepiness, and sensitivity to sleep deprivation.⁷¹⁻⁷⁴ There is evidence of neuronal injury in the hippocampus,^{75,76} the basal forebrain,⁷⁷ and the wake-promoting catecholaminergic system.⁷⁸ The mediating mechanisms include free radical injury, lipid peroxidation, induction of nitric oxide synthase, platelet activation, and apoptosis.⁷⁹⁻⁸¹ However, oxidative stress, especially modest hypoxia, may have a protective effect on the brain and cardiovascular system by activating gene programs that induce vascular remodeling as well as other protective responses; thereby, engendering resilience in the brain (known as ischemic preconditioning).⁸²

OSA is related to the surrogate index of stroke. Moderate-to-severe OSA is associated with silent ischemic changes, including white matter changes and lacunae as well as cerebral microbleeds.⁸³⁻⁸⁶ Carotid and intracranial atherosclerosis are also accelerated in OSA.^{87,88} It is unclear whether continuous positive airway pressure (CPAP) has a therapeutic effect on these changes.⁸⁹

Hypertension and insulin resistance might mediate the development of stroke in OSA. Moderate-to-severe OSA is significantly associated with prevalent and incident hypertension in a severity-dependent manner,^{90,91} and is highly prevalent in patients with resistant hypertension.⁹² Effective CPAP therapy, alone or in addition to antihypertensive medication, significantly reduces blood pressure.⁹³⁻⁹⁵ OSA may also increase the risk for development of type 2 diabetes by mechanisms such as increased insulin resistance and high cortisol secretion.^{12,96} In a 6-month parallel trial, the CPAP group achieved a greater decrease in HbA1c (−0.4%; 95% confidence interval [CI], −0.7% to −0.04%) than the control group.⁹⁷ Continuously supervised CPAP therapy (7.92 hr/night) improved glycemic control and insulin resistance.⁹⁸ However, the CPAP effect on glycemic control is less consistent than its effect on blood pressure. Concomitant obesity might have a stronger effect than OSA, not mitigated by CPAP therapy.

OSA is also associated with the risk for cardioembolism. Nearly 40% of symptomatic atrial fibrillation events are seen between midnight and 8:00 AM.⁹⁹ People with OSA have four times the odds of atrial fibrillation (odds ratio [OR], 4.02; 95% CI, 1.03 to 15.74).¹⁰⁰ Nocturnal oxygen desaturation is an independent risk factor for new onset atrial fibrillation.¹⁰¹ In a recent cohort study of 6,841 patients, OSA diagnosis and severity were associated with atrial fibrillation (hazard ratio [HR], 1.55; 95% CI, 1.21 to 2.00) during a follow-up of 12 years.¹⁰² Furthermore, OSA may potentiate the risk of cardioembolism or stroke in patients with atrial fibrillation.^{103,104} Several observa-

tional studies found an improvement or resolution of cardiac arrhythmia and atrial fibrillation after CPAP therapy.^{105,106}

In addition, sleep apnea is associated with inflammation,¹⁰⁷⁻¹¹⁰ endothelial dysfunction,^{111,112} hypercoagulability,¹¹³⁻¹¹⁵ and cerebral hemodynamic changes.¹¹⁶⁻¹¹⁸ The overall findings suggest that OSA contributes to the development of stroke through various mechanisms downstream to intermittent hypoxia, sleep fragmentation, and hemodynamic swings.^{9,12,46,70}

Observational findings

Sleep apnea is exceedingly common in the acute stroke setting, present in 50% to 70% of subjects with acute stroke or transient ischemic attacks, which is a higher frequency than observed in control groups.¹¹⁹⁻¹²² However, OSA and stroke share risk factors such as male sex, obesity, old age, hypertension, and smoking.^{62,65,66,68} An independent association between the two conditions was supported by large scale epidemiological studies including the Sleep Heart Health Study and the Wisconsin Sleep Cohort Study.^{48,123} In these studies, OSA with an apnea-hypopnea index (AHI) ≥ 20 /hr or >11 /hr was related to prevalent stroke, with an OR of 4.31 (95% CI, 1.31 to 14.15) and 1.58 (95% CI, 1.02 to 2.46), respectively, when adjusted for age, sex, weight, blood pressure, smoking, and other confounders. Prospective cohort studies in clinical or general populations followed, and the major findings are summarized in Table 1.^{47-49,124-128}

In the first study on the temporal relationship between OSA and stroke in the general population (from the Wisconsin Sleep Cohort), the causal association was attenuated (OR, 3.08; 95% CI, 0.74 to 12.81) when adjusted for age, sex, and body mass index.⁴⁸ The younger age of the cohort (mean age, 47 ± 8 years old) and a low incidence of stroke (1.3 per 1,000 person-years) probably weakened the statistical power. In the Sleep Heart Health Study (n=5,422; stroke incidence, 4.4 per 1,000 person-years), men with moderate-to-severe OSA (AHI >19 /hr), but not women, had a higher risk for ischemic stroke during follow-up (median, 8.7 years; HR, 2.86; 95% CI, 1.1 to 7.4). The lack of association in women was explained by insufficient statistical power (lower stroke incidence in women); the relatively shorter duration of OSA exposure (due to the later, usually postmenopausal, onset in women);¹²⁹ the higher rate of OSA progression along with aging during the follow-up, leading to a considerable probability of misclassification (OSA vs. control, or OSA severity); and the stronger effects of well-known vascular risk factors.⁴⁹ For elderly people of both sexes (aged 70 to 100 years, n=394), the risk of incident stroke was significantly higher for severe OSA (AHI ≥ 30 /hr; HR, 2.52) throughout a 6-year period of observation, independent of

Table 1. Studies of obstructive sleep apnea at risk for stroke

Study	Design	Number	Group	Primary outcome*	Risk factor adjustment
Arzt et al. (2005) ⁴⁸	General population cohort, follow-up at every 4 yr	1,189	AHI >20 vs. <5	Incident stroke OR, 3.08 (0.74–12.81)	Age, sex, and BMI
Redline et al. (2010) ⁴⁹	General population cohort, (median) 8.7 yr follow-up	5,422	AHI >19 vs. <4	Incident stroke Men: HR, 2.86 (1.10–7.39) Women: HR, 1.21 (0.65–2.24)	Age, BMI, smoking, blood pressure, antihypertensives, diabetes mellitus, and race
Marin et al. (2005) ¹²⁵	Clinic (OSA) and general population (control) cohort, 10.1 yr follow-up	1,010 men	Untreated severe OSA (AHI ≥30 or AHI 5–30 with severe daytime sleepiness) vs. AHI <5	Incident composite cardiovascular events Non-fatal: OR, 3.17 (1.12–7.51) Fatal: OR, 2.87 (1.17–7.51)	Age, cardiovascular disease, diabetes mellitus, hypertension, lipid disorders, smoking, alcohol, blood pressure, glucose, and lipid levels
Munoz et al. (2006) ¹²⁶	Clinic cohort, (mean) 4.5 yr follow-up	394	AHI >30 vs. 0–29	Incident stroke HR, 2.52 (1.04–6.10)	Sex (distribution of other risk factors were balanced between the two groups)
Yaggi et al. (2005) ⁴⁷	Clinic cohort, (median) 3.4 yr follow-up	1,022	AHI >5 vs. AHI <5	Incident stroke or death of any causes HR, 1.97 (1.12–3.48)	Age, race, sex, smoking, alcohol, BMI, atrial fibrillation, hypertension, and lipids
Yeboah et al. (2011) ¹²⁸	General population cohort, (mean) 7.5 yr follow-up	5,338	Physician diagnosed OSA vs. normal control	Incident cardiovascular events HR, 2.16 (1.30–3.58) All-cause mortality HR, 2.71 (1.45–5.08)	Age, gender, race/ethnicity, smoking, diabetes, total cholesterol, high-density lipoprotein, triglyceride, BMI, alcohol, benzodiazepine/statin/antihypertensive use
Young et al. (2008) ¹²⁷	General population cohort 18 yr follow-up	1,522	AHI >30 vs. AHI <5	Cardiovascular mortality HR, 5.2 (1.4–19.2) All-cause mortality HR, 3.8 (1.6–9.0)	Age, sex, BMI, smoking, alcohol, total cholesterol, and sleep duration

AHI, apnea-hypopnea index; OR, odds ratio; BMI, body mass index; HR, hazard ratio; OSA, obstructive sleep apnea.

*Adjusted OR or HR (95% confidence interval).

other vascular risk factors.¹²⁶

Prospective observational studies of clinic-based cohorts, assessing composite cardiovascular events as a primary endpoint, also suggested a role for OSA in the development of stroke.^{124,125} Peker et al.¹²⁴ reported an independent association of OSA with cardiovascular events in a small community sample of men (age, 30 to 69 years old; n=182) free from prevalent cardiovascular diseases, hypertension, and diabetes. During the 7-year follow-up, the OR for people with OSA having cardiovascular diseases (including stroke) was 4.9 (95% CI, 1.8 to 13.6), and effective treatment of OSA significantly reduced the risk (OR, 0.1; 95% CI, 0.0 to 0.7). The effect of treatment, as well as the contribution of OSA to cardiovascular event incidence, were demonstrated in a subsequent long-term observational study of a clinical population (mean observation period, 10.1 years; n=1,656).¹²⁵ The group of subjects with untreated severe OSA (AHI ≥30/hr or 5 to 29/hr with severe sleepiness) had a higher hazard for fatal and non-fatal cardiovascular diseases (HR, 2.87 and 3.17, respectively), compared with age- and body mass-matched controls. With an average nightly use of CPAP for at least 4 hours, the risk of incident cardiovascular events among subjects with severe or symptomatic OSA was

comparable to that of controls or simple snorers (AHI <5/hr). The cardiovascular effects of OSA are not limited to subjects with a severe burden of OSA. A prospective observational study in a clinical population (aged ≥50 years; n=1,022) free from myocardial infarction or stroke at study entry, found that the presence of OSA (AHI ≥5/hr) increased the risks for outcome events (stroke or death from any cause, HR, 1.97; 95% CI, 1.12 to 3.48) during the follow-up (median, 3.4 years).⁴⁷ However, the treatment effect was not substantial, even though a large proportion of OSA subjects had active treatments including meaningful weight reduction (31% with weight loss of ≥10% body weight), CPAP therapy (58%) with fair adherence (at least 4 hours of nightly use for ≥5 nights a week), and upper airway surgery (15%). The increased rates of stroke and death despite OSA treatment can be explained by older age (compared to a previous study¹²⁵), with correspondingly increased vascular risk, prolonged exposure to OSA prior to the treatment, a relatively shorter duration of intervention, and changes in treatment effectiveness (weight regained, reduced CPAP adherence, or loss of surgery effect).⁴⁷ The study was not designed a priori to investigate treatment effects. An increased risk of cardiovascular and non-cardiovascular death in the OSA group was also re-

ported from a longitudinal analysis of the Wisconsin Sleep Cohort and the Multi-Ethnic Study of Atherosclerosis cohort.^{127,128}

Summarizing the observational findings, prospective studies largely support a causal relationship between OSA and stroke (Table 1). Recent systematic meta-analyses reported that OSA was significantly associated with incident stroke (OR, 2.24; 95% CI, 1.57 to 3.19) (relative risk [RR], 2.02; 95% CI, 1.40 to 2.10).^{50,130} However a few important issues should be considered. First, the effects of well-established cardiovascular risk factors other than age, including hypertension, diabetes, atrial fibrillation, and smoking, were smaller than that of OSA, which was generally not significant.^{47,49,125,126} Optimal modification or treatment of well-established vascular risk factors was likely to reduce their influences on the outcomes in the study participants.¹²⁶ Second, the observational findings are inherently limited by study design and lack of randomization. The baseline characteristics among groups may differ by undefined factors other than chance. The "healthy adherer" effect, describing a better outcome in subjects compliant with any given intervention due to their health-conscious behavior or lifestyle, might bias the results in favor of CPAP therapy.^{131,132} Studies with randomized designs are required to provide a better understanding of the causal relationship between OSA and stroke, as well as the therapeutic efficacy of CPAP in the prevention of stroke.

Randomized clinical trials

Well-designed randomized clinical trials (RCTs) of CPAP therapy for primary prevention of clinical outcomes such as stroke, coronary heart disease, or atrial fibrillation are scarce.¹³³ In an RCT, feasibility and study design are critically influenced by the expected rate of the primary endpoint, the predicted efficacy (and precision in application) of therapy, and the estimated duration of intervention, all of which affect the sample size required for sufficient statistical power. To examine the effects of interventions on hard clinical endpoints (e.g., stroke in OSA) requires a larger sample size and longer period of observation than needed for trials with surrogate endpoints (e.g., blood pressure or inflammation in OSA). Therefore, to assess the effect of therapy (e.g., CPAP) on clinical outcomes, secondary prevention studies may be more feasible.^{134,135}

Recently the results from two RCTs were reported, testing the long-term efficacy of CPAP therapy for the prevention of cardiovascular events in subjects with established cardiovascular disease (coronary heart disease or stroke) and OSA.^{60,61} The Sleep Apnea Cardiovascular Endpoint (SAVE) trial was a multinational RCT including 2,717 non-sleepy subjects with moderate-to-severe OSA (AHI ≥ 15 /hr, but not with severe hypoxemia [oxygen desaturation $< 80\%$ for $> 10\%$ of recording time]) and

established stroke or cardiovascular disease, who were subsequently randomized either to usual care with CPAP therapy or to usual care alone, and were followed for a mean period of 3.7 years.⁶⁰ The study tested the hypothesis that additional CPAP therapy reduced the risk of future cardiovascular events (a composite of vascular mortality, myocardial infarction, stroke, or hospitalization for vascular events). During the follow-up, the CPAP therapy did not effectively lower the incidence of predefined events compared with the usual care (HR, 1.10; 95% CI, 0.91 to 1.32). In the CPAP group (n=1,346), the adherence was only 3.3 hours per night on average, and fair (≥ 4 hr/night) in less than half of the subjects (42%). During the run-in period of a week with sham CPAP that was introduced to maximize the treatment adherence of the study participants, the required threshold of minimal adherence was an average of 3 hours per night, equivalent to 50% adherence in those who sleep 6 hours daily. In the prespecified propensity-score-matched analysis to compare the group with fair CPAP adherence (n=561) with matched controls, the reduction in the composite endpoint was not significant (HR, 0.80; 95% CI, 0.60 to 1.07), but a lower risk of stroke was found (HR, 0.56; 95% CI, 0.32 to 1.00; $P=0.05$). Another RCT, the Randomized Intervention with CPAP in CAD and OSA (RICCADSA) trial, was performed in patients with coronary artery disease and concomitant non-sleepy OSA (n=244; AHI ≥ 15 /hr).⁶¹ During the follow-up (median, 56.9 months), the incidence of the primary composite endpoint (repeat revascularization, myocardial infarction, stroke, or cardiovascular mortality) was not different between the groups with and without CPAP therapy, but based on the per protocol analysis, the risk was significantly lower in the CPAP adherent group (nightly use ≥ 4 hours) than in the non-compliant group or the untreated group (HR, 0.29; 95% CI, 0.10 to 0.86).

Both the large (SAVE) and the small scale (RICCADSA) RCTs failed to demonstrate efficacy of CPAP therapy. Negative findings in such high-profile trials underscore the need for future trials, and are vital contributors to recognizing and addressing the key factors to be considered in the design of future studies.^{136,137} Several important aspects should be discussed in this context. Both trials included only non-sleepy OSA for ethical reasons (the expected harm to sleepy subjects if included but untreated). Excessive daytime sleepiness is a marker of higher levels of inflammation, insulin resistance, and blood pressure, compared with non-sleepy OSA.¹³⁸⁻¹⁴⁰ By excluding sleepy subjects, the study sample was limited to a potentially lower-risk group, thus reducing its statistical power. Preceding RCTs on non-sleepy OSA populations have demonstrated that CPAP therapy is not effective in reducing blood pressure and pre-

venting cardiovascular risk or events including incident hypertension, despite improvements in subjective sleepiness.¹⁴¹⁻¹⁴⁵ Therefore the lack of CPAP efficacy in trials performed with non-sleepy subjects cannot be generalized to severe or symptomatic OSA populations.

Another major issue is the therapeutic effectiveness of CPAP in these trials. CPAP adherence is a critical factor in therapeutic effectiveness. In the SAVE trial, the average nightly use was 3.3 hours, 20% of the subjects did not use CPAP at all, and only 42% used CPAP for at least 4 hours a night. The 4-hour threshold is an insurance-payment driven criterion widely enforced in the United States, which has gradually morphed into a clinical standard. The flaw in this sort of "criteria creep" is emphasized. Such a low adherence may have contributed to the null findings, as the residual apnea burden (see below) is substantial. Adherence to CPAP has modified efficacy in previous trials:¹⁴⁵⁻¹⁴⁷ the higher the adherence, the better the outcome. A dose-response association between CPAP adherence and cardiovascular outcome was found in the SAVE and RIC-CADSA trials, in which CPAP adherence was related to a lower risk of stroke (HR, 0.56; 95% CI, 0.32 to 1.00) or cardiovascular endpoints (HR, 0.29; 95% CI, 0.10 to 0.86).^{60,61} However these findings came from secondary or on-treatment analysis, possibly biased by multiple comparisons or a healthy adherer effect.^{131,132} In addition to adherence, the timing and the duration of CPAP-off periods affect therapeutic effectiveness.¹⁴⁸⁻¹⁵² The CPAP-off time is likely to predominate in the latter half of the night, when REM sleep is prevalent. OSA events during REM sleep are generally prolonged and associated with severe oxygen desaturation. Sleep apnea during REM, but not during NREM sleep, has been associated with hypertension, non-dipping of nocturnal blood pressure, and insulin resistance, even in subjects not considered to have OSA (AHI <5/hr).¹⁵³⁻¹⁵⁶ In recent observational finding from the Sleep Heart Health Study, severe REM OSA (AHI during REM sleep ≥ 30 /hr) was associated with a higher incidence of cardiovascular events in the group with prevalent cardiovascular disease.¹⁵⁷ The cardiovascular effects of REM OSA have several important implications. The timing and duration of the CPAP-off periods as well as the subjects' sleep should be documented to define and interpret the effectiveness of intervention. The residual apnea burden, including REM OSA, is directly influenced by the proportion and timing of CPAP-on and -off periods.¹⁴⁸⁻¹⁵⁰ In future trials, a predefined secondary analysis of REM OSA should be performed, considering its significant cardiovascular effects and prevalence.¹⁵⁸ REM OSA in subjects with AHI of <5/hr may bias the results of RCTs, especially secondary prevention trials.¹⁵⁷ From a diagnostic standpoint, simple cardiorespiratory moni-

toring devices, for example, a portable device consisting of air-flow and oximetry, should not be used in future trials. Such a home kit cannot reliably detect REM OSA, central sleep apnea, and periodic limb movements (PLMs).¹⁵⁹ The latter two conditions are not only commonly present in high risk populations for cardiovascular events (such as the elderly or subjects with established cardiovascular diseases or stroke), but also increase the cardiovascular risk of these individuals.¹⁶⁰⁻¹⁶⁴

Finally, there is clear evidence that what is called OSA is a complex pathophysiological condition, with multiple and often interacting disease drivers.¹⁶⁵⁻¹⁶⁷ These include upper airway collapsibility, impaired negative pressure response, reduced arousal threshold and high loop gain. The first three become irrelevant when the airway is adequately supported, but high loop gain will cause ongoing respiratory control instability and a high residual apnea burden or treatment intolerance. The risk of high loop gain is increased in those with cardiovascular comorbidities, setting the stage for impaired therapeutic responses.¹⁶⁶ Multi-modal therapy, such as low dose acetazolamide plus CPAP,^{168,169} may reasonably be considered in future clinical trials. The quality of data, specifically direct visualization of respiratory waveforms from current generation CPAP devices, can also detect residual disease burden and help identify those who could benefit from multi-modal therapy.¹⁷⁰ The question should not be whether CPAP is beneficial, but whether effective sleep therapy is beneficial.

Previous RCTs on cardiovascular outcomes usually adopted composite endpoints, mainly due to considerations of feasibility and statistical power. However, for future trials, therapeutic efficacy needs to be tested separately for each type of cardiovascular endpoint. Stroke is a primary candidate for this purpose. In CPAP trials and observational studies, OSA was more strongly related to stroke than to other cardiovascular diseases. In the SAVE trial, CPAP adherence led to the reduced risk of stroke (HR, 0.56; 95% CI, 0.32 to 1.00), and untreated OSA in women was associated with an increased incidence of cardiovascular events, particularly stroke (HR for stroke, 6.44; 95% CI, 1.46 to 28.3; and HR for coronary heart disease, 1.77; 95% CI, 0.76 to 4.09), which is concordant with the findings of the Sleep Heart Health Study concerning the relationship between OSA and stroke occurrence.^{49,60,171}

To summarize, we caution against discarding the benefit of CPAP therapy for the prevention of stroke and other cardiovascular events in OSA on the basis of results from the currently available RCTs. The overall findings suggest what really matters is the therapeutic effectiveness, which is determined by CPAP adherence, CPAP efficacy, apnea burden,¹⁴⁸⁻¹⁵⁰ and possibly disease phenotype.¹⁶⁵⁻¹⁶⁷ Apnea burden is driven by residual or

Table 2. Studies between sleep duration and risk of stroke or mortality

Study	Design	Number	Major findings*
Chen et al. (2008) ¹⁷²	Cohort 7.5 yr follow-up	93,175 women	≤6 hr of sleep : RR for ischemic stroke, 1.22 (1.03–1.44) 8 hr, 9 hr of sleep : RR for ischemic stroke, 1.14 (0.97–1.33), 1.24 (1.04–1.47)
Helbig et al. (2015) ¹⁷³	Cohort 14 yr (mean) follow-up	17,604	≤5 hr of sleep : HR for stroke, 1.44 (1.01–2.06) ≥10 hr of sleep : HR for stroke, 1.63 (1.16–2.29)
Kawachi et al. (2016) ¹⁸¹	Cohort 17 yr follow-up	27,896	≥9 hr of sleep : HR for stroke mortality, 1.51 (1.16–1.97) : HR for ischemic stroke mortality, 1.65 (1.16–2.35)
Leng et al. (2015) ⁵¹	Cohort 9.5 yr follow-up	9,692	≥8–9 hr of sleep : HR for stroke, 1.46 (1.08–1.98)
Pan et al. (2014) ¹⁷⁸	Cohort 14.7 yr follow-up	63,257	≤5 hr of sleep : HR for stroke mortality, 1.25 (1.05–1.50) ≥9 hr of sleep : HR for stroke mortality, 1.54 (1.28–1.85)
Qureshi et al. (1997) ¹⁸²	Cohort 10 yr follow-up	7,844	>8 hr of sleep : RR for stroke, 1.5 (1.1–2.0) >8 hr of sleep with daytime somnolence : RR for stroke, 1.9 (1.2–3.1)
von Ruesten et al. (2012) ¹⁷⁴	Cohort 7.8 yr (mean) follow-up	23,620	<6 hr of sleep : HR for stroke, 2.06 (1.18–3.59)
He et al. (2017) ⁵²	Meta-analysis 7.8–14.7 yr follow-up	528,653	RR for stroke (7 hr as reference) : 4 hr, 1.17 (0.99–1.38); 5 hr, 1.17 (1.00–1.37); 6 hr, 1.10 (1.00–1.21); 8 hr, 1.17 (1.07–1.28); 9 hr, 1.45 (1.23–1.70); 10 hr, 1.64 (1.4–1.92)
Li et al. (2016) ¹⁷⁵	Meta-analysis 3–18 yr follow-up	522,163	Short sleep duration (7 hr as reference) : RR for stroke, 1.07 (1.02–1.12) for each 1-hr shorter Long sleep duration (7 hr as reference) : RR for stroke, 1.17 (1.14–1.20) for each 1-hr increase : RR for stroke mortality, 1.17 (1.13–1.20) per 1-hr increase

RR, relative risk; HR, hazard ratio.

*Adjusted HR or RR (95% confidence interval).

emergent sleep apnea during CPAP-on and-off periods along with the duration of CPAP-off periods.^{150–152,170} In future trials for primary and secondary prevention in OSA, we need to adopt methods to determine the therapeutic effectiveness by measuring apnea burden, and to test whether effective therapy (defined by minimal or sufficiently low apnea burden, e.g., measured average AHI <5 over the entire treatment period including both CPAP-on and -off state in sleep) reduces the risk of stroke and other cardiovascular events.

Sleep duration and insomnia

Sleep duration

The relationship between sleep duration and stroke incidence is U-shaped in general; the risk for stroke is elevated in both short and long sleep groups.^{172–174} In a recent meta-analysis (n=559,252), the pooled HR for stroke was 1.15 (95% CI, 1.07 to 1.24) for short sleep and 1.45 (95% CI, 1.30 to 1.62) for long

sleep duration.⁵¹ In another study, the pooled RR for stroke was 1.07 (95% CI, 1.02 to 1.12) and 1.17 (95% CI, 1.14 to 1.20) for each 1-hour decrease and increase in sleep duration, respectively.¹⁷⁵

Short sleep, commonly defined as <5 to 6 hours of nocturnal sleep, increases the risks of stroke, coronary heart disease, and death (Table 2).^{52,173,175–180} In a large-scale prospective study of older women (Women's Health Initiative Study; age, 50 to 79 years; n=93,175), short sleep (≤6 hours) was associated with ischemic stroke (HR, 1.22; 95% CI, 1.03 to 1.44) in the group free from cardiovascular diseases and diabetes at the baseline.¹⁷² Despite the large sample size, the study was limited by the participants' characteristics, as enrollment was restricted to postmenopausal women. In the European Prospective Investigation into Cancer and Nutrition-Potsdam Study (n=23,620; age, 35 to 65 years; men 38.6%), subjects with short sleep (<6 hours) had a significantly increased risk for stroke (HR, 2.06; 95% CI, 1.18 to 3.59) during the 8-year follow-up.¹⁷⁴ In another

er population-based prospective study (n=17,604; age, 25 to 74 years; mean follow-up, 14 years), short sleep (≤ 5 hours) was significantly associated with stroke in men (HR, 1.44; 95% CI, 1.01 to 2.06).¹⁷³

Long sleep duration (more than 9 hours of sleep) is also associated with stroke and cardiovascular mortality.^{51,178,179,181,182} Qureshi et al.¹⁸², using the First National Health and Nutrition Examination Survey (NHANES I), reported that stroke risk was higher in people who reported sleeping for >8 hours than for those who slept 6 to 8 hours (RR, 1.5; 95% CI, 1.1 to 2.1). In a recent population-based prospective study of 9,692 stroke-free participants, long sleep (HR, 1.46; 95% CI, 1.08 to 1.98), but not short sleep (HR, 1.18; 95% CI, 0.91 to 1.53), was associated with a higher risk of stroke.⁵¹

The association between sleep duration and stroke mortality has been assessed in several prospective studies^{178,183} and meta-analyses.^{52,175,184} The Singapore Chinese Health Study (n=63,257) showed that long (≥ 9 hours) and short (≤ 5 hours) sleep duration (compared with 7 hours of sleep) were significantly associated with increased risk for total stroke mortality (HR, 1.54; 95% CI, 1.28 to 1.85; and HR, 1.25; 95% CI, 1.05 to 1.50, respectively).¹⁷⁸ A meta-analysis showed that stroke mortality increased at either end of the sleep duration range.¹⁸⁴ However, other studies have found that the risk of stroke mortality increased only for long sleep duration, not for short sleep.^{52,175,181,183}

When interpreting the relationship between sleep duration and the risk of stroke or mortality, a few issues need to be considered. First, in most epidemiologic studies the assessment of sleep duration was based on self-report, not on objective measurement. Although self-reported sleep duration generally correlates to a degree with the duration measured by actigraphy or polysomnography,^{185,186} reported sleep duration is systematically over-estimated, especially in short sleepers, compared with objectively measured sleep duration.¹⁸⁷ Second, long sleep has a greater effect on mortality than short sleep,^{52,181,188} which can be explained by differences in the driving forces for each end of the sleep spectrum. In contrast to short sleep, which commonly results from voluntary sleep curtailment due to social requirements or individual preferences, long sleep indicates an increased need for sleep, especially in the elderly, influenced by comorbid medical conditions such as chronic devastating illness or inflammation.^{52,189-191} Short sleep is a modifiable behavioral risk factor with a small but significant impact on cardiovascular morbidity and mortality. Long sleep is an indicator of comorbid medical conditions that confer higher mortality and vascular risk. A longitudinal observational study of the Whitehall II Cohort demonstrated the differential effects of

short and long sleep: a decrease in sleep duration was associated with increased cardiovascular mortality, while an increase was related to non-cardiovascular death.¹⁹²

The linking mechanisms between short sleep and cardiovascular events include obesity, impaired glucose metabolism, hypertension, and dyslipidemia. Sleep loss contributes to the development of obesity or weight gain by disturbing the balance between energy intake and expenditure. Sleep deprivation leads to increased levels of the appetite stimulating hormone ghrelin and reduced levels of the anti-appetite hormone leptin.^{193,194} Furthermore, reduced physical activity associated with sleep deprivation leads to weight gain by decreasing energy expenditure.^{195,196} Short sleep is also associated with sympathetic overactivity,¹⁹⁷ which leads to impaired glucose metabolism,^{180,198} hypertension, and non-dipping of blood pressure.^{176,199,200} Sleep loss alters lipid metabolism.^{177,201,202} Insufficient sleep activates inflammatory pathways, as indicated by increased levels of C-reactive protein and interleukin-6.^{203,204}

Long sleep duration has been suggested as a potential marker for subsequent stroke risk.^{51,52,175,181,182} The linking mechanisms between long sleep and stroke are still elusive, but increased inflammation and abnormal lipid profiles in long sleepers have recently been reported.^{202,205} Long sleep has been associated with cardiovascular conditions including carotid artery atherosclerosis,²⁰⁶ atrial fibrillation,^{207,208} and white matter hyperintensities.²⁰⁹

In summary, both short and long sleep duration are associated with a higher risk for stroke and mortality. Each end of the sleep duration spectrum has different implications. Short sleep confers an increased risk for cardiovascular events and mortality, via effects on blood pressure, glucose and lipid metabolism.^{52,175,210,211} Long sleep is often an epiphenomenon of comorbidities that are commonly associated with increased sleep fragmentation, depressive symptoms, and poor general health.²¹² The effects of sleep duration can have substantial long-term consequences, considering the increasing longevity of humans. Interventions such as sleep extension in short sleepers might reduce the cardiovascular risks. Simple measures to cope with sleep debt such as napping or weekend sleep extension might have a meaningful impact at the population level. Recent studies found that weekend catch-up sleep was associated with a lower risk of hypertension and obesity.^{213,214}

Insomnia

Insomnia is prevalent in approximately 10% to 20% of the adult population, with approximately 50% having a chronic form.²¹⁵ Chronic insomnia disorder is characterized by a complaint of difficulty initiating sleep and maintaining sleep, and

Table 3. Studies of insomnia, PLMS, RLS as a prognostic factor for stroke and mortality

Study	Design	Number	Major findings*
Insomnia			
Chien et al. (2010) ²¹⁷	Cohort 15.9 yr (median) follow-up	3,430	RR for CAD/stroke, 1.8 (1.0–3.1) RR for mortality, 1.7 (1.2–2.5)
Phillips et al. (2007) ²¹⁹	Cohort 6 yr follow-up	11,863	OR for hypertension, 1.2 (1.0–1.3) OR for CVD, 1.5 (1.1–2.0)
Vgontzas et al. (2009) ²²⁰	Cross-sectional	1,741	<5 hr vs. >6 hr of sleep : HR for hypertension, 5.1 (2.2–11.8); OR for diabetes, 3.0 (1.2–7.0)
Wu et al. (2014) ⁵³	Cohort 4 yr follow-up	21,438	Insomniacs vs. non-insomniacs : adjusted HR for stroke, 1.54 (1.38–1.72)
PLMS			
Kendzerska et al. (2014) ²²⁵	Retrospective 5.7 yr (median) follow-up	10,149	PLMI 13.4 vs. 0 : OR for stroke, 1.01 (0.94–1.09); OR for mortality, 1.05 (1.02–1.07)
Koo et al. (2011) ⁵⁵	Cohort 4.4 yr follow-up	2,911 men	PLMI >30 vs. <5 : OR for CVD, 1.25 (1.00–1.56)
RLS			
Elwood et al. (2006) ²³¹	Cohort 10 yr follow-up	1,874 men	OR for stroke, 1.67 (1.07–2.60)
Molnar et al. (2016) ²³²	Cohort 8.1 yr follow-up	7,392	HR for stroke, 3.89 (3.07–4.94)
Szentkirályi et al. (2013) ²³³	Cohort 6–11 yr follow-up	DHS: 1,312 SHIP: 4,308	OR for stroke DHS: 1.59 (0.17–15.16) SHIP: 1.20 (0.46–3.17)
Winkelman et al. (2008) ²³⁰	Cross-sectional	3,433	OR for hypertension, 1.3 (0.9–1.8) OR for CAD/stroke, 2.4 (1.6–3.7)
Winter et al. (2013) ²³⁴	Cohort 6 yr follow-up	48,938	OR for stroke (women), 1.29 (0.91–1.82) OR for CVD mortality (men), 1.22 (0.87–1.70)

PLMS, periodic limb movements during sleep; RLS, restless leg syndrome; RR, relative risk; CAD, coronary artery disease; CVD, cardiovascular disease; HR, hazard ratio; OR, odds ratio; PLM, periodic limb movement; PLMI, periodic limb movement index; DHS, Dortmund Health Study; SHIP, Study of Health in Pomerania.

*Adjusted RR, OR, or HR (95% confidence interval).

waking up earlier than desired. The diagnosis of chronic insomnia requires occurrences on at least three nights per week for at least 3 months.²¹⁶ Insomnia was found to be a risk factor for cardiovascular events and death in several studies.^{190,217}

Sleep questionnaire-based studies have reported a significant association between insomnia symptoms and cardiovascular outcomes.²¹⁸ In a prospective study of 11,863 participants, subjective insomnia complaints were associated with an increased risk of hypertension and cardiovascular disease.²¹⁹ A large study of 21,438 subjects with insomnia and 64,314 matched controls found that the insomnia group had a 54% higher risk for stroke over a 4-year follow-up period than the control group.⁵³ However, these studies had the limitation that the diagnosis of insomnia was based solely on self-reported assessments or questionnaires for insomnia complaints, meaning that the sleep latency and time of being awake after sleep onset were generally overestimated.

Insomnia with objective short sleep duration (<5 hours on

polysomnography), suggested as the most biologically vulnerable phenotype, carries a higher risk for impaired heart rate variability, hypertension, diabetes, neurocognitive impairment, and mortality, compared with insomnia with longer objective sleep (Table 3).^{11,220–222} Insomnia with objective short sleep may show better response to biological treatments, whereas insomnia with objective normal sleep may show better responses to psychological interventions than to biological treatments.¹¹ Elevated sympathetic and hypothalamic-pituitary-adrenal axis activity has been proposed as a mechanism for the cardiovascular effect of insomnia.^{11,220}

Periodic limb movements during sleep and restless legs syndrome

The defining feature of PLMS is periodic episodes of repetitive, highly stereotyped limb movements during sleep, which mostly occur in the lower extremities and can be associated with cor-




Figure 3. Periodic limb movements during sleep. (A) Electroencephalography (EEG) plots for 30-second epoch. Arousal (arrowhead in panel A) is accompanied by periodic limb movement (arrowhead in panel B) during stage 2 rapid-eye-movement (REM) and non-REM sleep. The closed arrowheads in panels A and B indicate the same time. (B) Movement event plots for 2-minute epoch. Heart rate surges (open arrows) are associated with periodic brief electromyography (EMG) bursts in left or right tibialis anterior (close arrows). L, left; R, right; EOG, electrooculography; EKG, electrocardiogram; TA, tibialis anterior.

tical arousal (Figure 3).²¹⁶ The presence and severity of PLMS is determined by the average number of PLMs per hour of sleep (PLM index). PLM is commonly present in the general population (4.3% to 9.3% with PLM index >15/hr) and even more commonly in restless legs syndrome (RLS) patients (80% to 88% with PLM index >5/hr).^{223,224} PLM is not specific for RLS, as it is commonly seen with increasing age and in other medical disorders.²²⁴ A positive relationship between PLM and cardiovascular events or mortality has been demonstrated in observational studies, and a greater risk attributed to PLM combined with arousals.^{55,164,225,226} PLM with arousal induces an abrupt increase in blood pressure and heart rate through sympathetic overshoot.^{227,228}

RLS is a chronic sensorimotor disorder characterized by an irresistible urge to move the limbs, which is usually worse at rest, occurs predominantly in the evening or night time, and is relieved by movement such as walking or stretching.^{216,229} The prevalence of RLS in the general population has been reported to be between 5% and 10%, but it has been under-recognized.¹⁶⁴ RLS and its associated condition PLM may increase the risk for cardiovascular and cerebrovascular diseases.²³⁰ Several studies showed that RLS might be a prognostic factor for stroke, although others obtained conflicting results (Table 3).²³⁰⁻²³⁴ In a large prospective cohort study, RLS tended to be associated with an elevated risk of total and cardiovascular mortality, and

this association between RLS and mortality increased in women with a longer duration of RLS diagnosis.^{235,236} However, two meta-analyses assessing RLS as a risk factor for incident cardiovascular events and all-cause mortality were inconclusive.^{163,164} More severe, longer duration exposures, and secondary forms of RLS were associated with increased risk for stroke.^{164,230,237}

Sympathetic overactivity, metabolic dysregulation, inflammation, oxidative stress, peripheral hypoxia, and hypothalamic-pituitary-adrenal activation have been proposed as possible linking mechanisms between PLM/RLS and cardiovascular diseases.²³⁸ Repeated nocturnal fluctuations in heart rate and blood pressure that are associated with PLM and related microarousals cause daytime hypertension, subsequently increasing the risk for cerebrovascular diseases.^{227,228} In a prospective study of 3,116 elderly men, PLM increased atrial fibrillation risk in age-dependent manner.²³⁹

Circadian rhythm disorders and stroke

Circadian rhythms are endogenous biological rhythms with near-24-hour periodicity. The internal near-24-hour circadian pacemaker is entrained to the 24-hour light-dark cycle by exogenous cues (primarily light/dark cues, but also eating, and to lesser degrees exercise and social interactions).²¹⁶ Shift workers

are vulnerable to disruption of normal circadian rhythms. Shift work sleep disorder is characterized by complaints of excessive sleepiness or insomnia that occur when work hours overlap with the usual sleep time. Night shift work is associated with significant interference with the endogenous nocturnal blood pressure decline, resulting in abnormally elevated blood pressure during the shift that persists into the following day.⁵⁷ Shift workers are at risk for obesity, hypertension, diabetes, cardiovascular disease, and overall mortality.²⁴⁰⁻²⁴³ In a cohort study of 80,108 nurses, rotating night shift work was associated with a 40% increased risk of ischemic stroke for every 5 years of exposure, after adjusting for standard vascular risk factors.⁵⁸ A recent systematic meta-analysis demonstrated that shift work was associated with ischemic stroke (RR, 1.05; 95% CI, 1.01 to 1.09), although the original studies showed mixed results.²⁴⁴ Further studies should attempt to clarify the relationship between circadian rhythm disorders (including shift work sleep disorder) and stroke risk, as shift work is common and likely to increase.

Conclusions

Sleep disorders are highly prevalent in patients at risk for stroke, and may be modifiable risk factors for stroke. OSA increases the risk of stroke independently, but the reported lack of therapeutic effectiveness of CPAP for stroke prevention and cardiovascular protection should be cautiously interpreted. New clinical trials with improved therapeutic precision are necessary. Short or long sleep duration, and insomnia with objective short sleep duration, could be risk factors for stroke and mortality. Sleep-related movement disorders, including PLMS and RLS, are also potential risk factors for stroke. The overall findings suggest that systematic screening and proper management of sleep disturbances can substantially contribute to stroke risk modification at the population level.

Disclosure

Robert J. Thomas is co-inventor and patent holder of the ECG-derived sleep spectrogram, which may be used to phenotype sleep quality and central/complex sleep apnea. The technology is licensed by Beth Israel Deaconess Medical Center to MyCardio, LLC. He is also co-inventor and patent holder of the Positive Airway Pressure Gas Modulator, being developed for treatment of central/complex sleep apnea. He is a consultant in software development for DeVilbiss. The other authors have no financial conflicts of interest.

References

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2095-2128.
2. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet* 2014;383:245-254.
3. Koton S, Schneider AL, Rosamond WD, Shahar E, Sang Y, Gottesman RF, et al. Stroke incidence and mortality trends in US communities, 1987 to 2011. *JAMA* 2014;312:259-268.
4. Thrift AG, Howard G, Cadilhac DA, Howard VJ, Rothwell PM, Thayabaranathan T, et al. Global stroke statistics: an update of mortality data from countries using a broad code of "cerebrovascular diseases". *Int J Stroke* 2017;12:796-801.
5. Hong KS, Bang OY, Kang DW, Yu KH, Bae HJ, Lee JS, et al. Stroke statistics in Korea: part I. Epidemiology and risk factors: a report from the Korean Stroke Society and Clinical Research Center for Stroke. *J Stroke* 2013;15:2-20.
6. Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, et al. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet Neurol* 2016;15:913-924.
7. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet* 2010;376:112-123.
8. Béjot Y, Daubail B, Jacquin A, Durier J, Osseby GV, Rouaud O, et al. Trends in the incidence of ischaemic stroke in young adults between 1985 and 2011: the Dijon Stroke Registry. *J Neurol Neurosurg Psychiatry* 2014;85:509-513.
9. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. *J Am Coll Cardiol* 2008;52:686-717.
10. Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. *Eur Heart J* 2011;32:1484-1492.
11. Vgontzas AN, Fernandez-Mendoza J, Liao D, Bixler EO. In-

- somnia with objective short sleep duration: the most biologically severe phenotype of the disorder. *Sleep Med Rev* 2013;17:241-254.
12. Reutrakul S, Mokhlesi B. Obstructive sleep apnea and diabetes: a state of the art review. *Chest* 2017;152:1070-1086.
 13. Winkelman JW, Blackwell T, Stone K, Ancoli-Israel S, Redline S. Associations of incident cardiovascular events with restless legs syndrome and periodic leg movements of sleep in older men, for the outcomes of Sleep Disorders in Older Men Study (MrOS Sleep Study). *Sleep* 2017;40:zsx023.
 14. Anothaisintawee T, Reutrakul S, Van Cauter E, Thakkinstian A. Sleep disturbances compared to traditional risk factors for diabetes development: systematic review and meta-analysis. *Sleep Med Rev* 2016;30:11-24.
 15. Knutson KL, Van Cauter E. Associations between sleep loss and increased risk of obesity and diabetes. *Ann N Y Acad Sci* 2008;1129:287-304.
 16. Ford ES, Cunningham TJ, Croft JB. Trends in self-reported sleep duration among us adults from 1985 to 2012. *Sleep* 2015;38:829-832.
 17. Yetish G, Kaplan H, Gurven M, Wood B, Pontzer H, Manger PR, et al. Natural sleep and its seasonal variations in three pre-industrial societies. *Curr Biol* 2015;25:2862-2868.
 18. Saper CB, Fuller PM. Wake-sleep circuitry: an overview. *Curr Opin Neurobiol* 2017;44:186-192.
 19. Verrier RL, Harper RM. Cardiovascular physiology: central and autonomic regulation. In: Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep Medicine. 5th ed. St. Louis, MO: Elsevier Saunders, 2011;215-225.
 20. O'Brien E. Dipping comes of age: the importance of nocturnal blood pressure. *Hypertension* 2009;53:446-447.
 21. Javaheri S, Redline S. Sleep, slow-wave sleep, and blood pressure. *Curr Hypertens Rep* 2012;14:442-448.
 22. Redline S, Kirchner HL, Quan SF, Gottlieb DJ, Kapur V, Newman A. The effects of age, sex, ethnicity, and sleep-disordered breathing on sleep architecture. *Arch Intern Med* 2004;164:406-418.
 23. Mancia G. Autonomic modulation of the cardiovascular system during sleep. *N Engl J Med* 1993;328:347-349.
 24. Somers VK, Dyken ME, Mark AL, Abboud FM. Sympathetic-nerve activity during sleep in normal subjects. *N Engl J Med* 1993;328:303-307.
 25. Halász P, Terzano M, Parrino L, Bódizs R. The nature of arousal in sleep. *J Sleep Res* 2004;13:1-23.
 26. Carrington MJ, Trinder J. Blood pressure and heart rate during continuous experimental sleep fragmentation in healthy adults. *Sleep* 2008;31:1701-1712.
 27. Wu Y, Huang R, Zhong X, Xiao Y. Cardiovascular consequences of repetitive arousals over the entire sleep duration. *Biomed Res Int* 2017;2017:4213861.
 28. Hermida RC, Ayala DE, Smolensky MH, Fernández JR, Mojón A, Portaluppi F. Sleep-time blood pressure: unique sensitive prognostic marker of vascular risk and therapeutic target for prevention. *Sleep Med Rev* 2017;33:17-27.
 29. Smolensky MH, Hermida RC, Ayala DE, Portaluppi F. Bedtime hypertension chronotherapy: concepts and patient outcomes. *Curr Pharm Des* 2015;21:773-790.
 30. Smolensky MH, Hermida RC, Portaluppi F. Circadian mechanisms of 24-hour blood pressure regulation and patterning. *Sleep Med Rev* 2017;33:4-16.
 31. Bankir L, Bochud M, Maillard M, Bovet P, Gabriel A, Burnier M. Nighttime blood pressure and nocturnal dipping are associated with daytime urinary sodium excretion in African subjects. *Hypertension* 2008;51:891-898.
 32. Birkenhäger AM, van den Meiracker AH. Causes and consequences of a non-dipping blood pressure profile. *Neth J Med* 2007;65:127-131.
 33. Bouhanick B, Bongard V, Amar J, Bousquet S, Chamontin B. Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patients. *Diabetes Metab* 2008;34:560-567.
 34. Hassan MO, Jaju D, Albarwani S, Al-Yahyaee S, Al-Hadabi S, Lopez-Alvarenga JC, et al. Non-dipping blood pressure in the metabolic syndrome among Arabs of the Oman family study. *Obesity (Silver Spring)* 2007;15:2445-2453.
 35. Mellman TA, Brown DD, Jenifer ES, Hipolito MM, Randall OS. Posttraumatic stress disorder and nocturnal blood pressure dipping in young adult African Americans. *Psychosom Med* 2009;71:627-630.
 36. Kastarinen H, Vasunta RL, Ukkola O, Kesäniemi YA. Glomerular filtration rate is related to dipping pattern in ambulatory blood pressure monitoring: a cross-sectional population-based study. *J Hum Hypertens* 2010;24:247-253.
 37. Kario K, Shimada K, Pickering TG. Abnormal nocturnal blood pressure falls in elderly hypertension: clinical significance and determinants. *J Cardiovasc Pharmacol* 2003;41 Suppl 1:S61-S66.
 38. Loredó JS, Ancoli-Israel S, Dimsdale JE. Sleep quality and blood pressure dipping in obstructive sleep apnea. *Am J Hypertens* 2001;14:887-892.
 39. Loredó JS, Nelesen R, Ancoli-Israel S, Dimsdale JE. Sleep quality and blood pressure dipping in normal adults. *Sleep* 2004;27:1097-1103.
 40. Matthews KA, Kamarck TW, Hall MH, Strollo PJ, Owens JF, Buysse DJ, et al. Blood pressure dipping and sleep distur-

- bance in African-American and Caucasian men and women. *Am J Hypertens* 2008;21:826–831.
41. Routledge FS, McFetridge-Durdle JA, Dean CR; Canadian Hypertension Society. Night-time blood pressure patterns and target organ damage: a review. *Can J Cardiol* 2007;23:132–138.
 42. Bastos JM, Bertoquini S, Silva JA, Polónia J. Relationship between ambulatory blood pressure monitoring values and future occurrence of ischemic cerebrovascular and coronary events in hypertensive patients. *Rev Port Cardiol* 2006;25:305–316.
 43. Yamamoto Y, Akiguchi I, Oiwa K, Hayashi M, Ohara T, Ozasa K. The relationship between 24-hour blood pressure readings, subcortical ischemic lesions and vascular dementia. *Cerebrovasc Dis* 2005;19:302–308.
 44. Hajjar I, Zhao P, Alsop D, Abduljalil A, Selim M, Novak P, et al. Association of blood pressure elevation and nocturnal dipping with brain atrophy, perfusion and functional measures in stroke and nonstroke individuals. *Am J Hypertens* 2010;23:17–23.
 45. Hajjar I, Selim M, Novak P, Novak V. The relationship between nighttime dipping in blood pressure and cerebral hemodynamics in nonstroke patients. *J Clin Hypertens (Greenwich)* 2007;9:929–936.
 46. Redline S, Foody J. Sleep disturbances: time to join the top 10 potentially modifiable cardiovascular risk factors? *Circulation* 2011;124:2049–2051.
 47. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med* 2005;353:2034–2041.
 48. Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of sleep-disordered breathing and the occurrence of stroke. *Am J Respir Crit Care Med* 2005;172:1447–1451.
 49. Redline S, Yenokyan G, Gottlieb DJ, Shahar E, O'Connor GT, Resnick HE, et al. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. *Am J Respir Crit Care Med* 2010;182:269–277.
 50. Loke YK, Brown JW, Kwok CS, Niruban A, Myint PK. Association of obstructive sleep apnea with risk of serious cardiovascular events: a systematic review and meta-analysis. *Circ Cardiovasc Qual Outcomes* 2012;5:720–728.
 51. Leng Y, Cappuccio FP, Wainwright NW, Surtees PG, Luben R, Brayne C, et al. Sleep duration and risk of fatal and nonfatal stroke: a prospective study and meta-analysis. *Neurology* 2015;84:1072–1079.
 52. He Q, Sun H, Wu X, Zhang P, Dai H, Ai C, et al. Sleep duration and risk of stroke: a dose-response meta-analysis of prospective cohort studies. *Sleep Med* 2017;32:66–74.
 53. Wu MP, Lin HJ, Weng SF, Ho CH, Wang JJ, Hsu YW. Insomnia subtypes and the subsequent risks of stroke: report from a nationally representative cohort. *Stroke* 2014;45:1349–1354.
 54. Fernandez-Mendoza J, Baker JH, Vgontzas AN, Gaines J, Liao D, Bixler EO. Insomnia symptoms with objective short sleep duration are associated with systemic inflammation in adolescents. *Brain Behav Immun* 2017;61:110–116.
 55. Koo BB, Blackwell T, Ancoli-Israel S, Stone KL, Stefanick ML, Redline S, et al. Association of incident cardiovascular disease with periodic limb movements during sleep in older men: outcomes of sleep disorders in older men (MrOS) study. *Circulation* 2011;124:1223–1231.
 56. Ferri R, Zucconi M. Heart rate and spectral EEG changes accompanying periodic and isolated leg movements during sleep. *Sleep* 2008;31:16–17.
 57. Lo SH, Lin LY, Hwang JS, Chang YY, Liao CS, Wang JD. Working the night shift causes increased vascular stress and delayed recovery in young women. *Chronobiol Int* 2010;27:1454–1468.
 58. Brown DL, Feskanich D, Sanchez BN, Rexrode KM, Schernhammer ES, Lisabeth LD. Rotating night shift work and the risk of ischemic stroke. *Am J Epidemiol* 2009;169:1370–1377.
 59. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d'Ortho MP, Erdmann E, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. *N Engl J Med* 2015;373:1095–1105.
 60. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. *N Engl J Med* 2016;375:919–931.
 61. Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunström E. Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with non-sleepy obstructive sleep apnea. The RICCADSA randomized controlled trial. *Am J Respir Crit Care Med* 2016;194:613–620.
 62. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 1993;328:1230–1235.
 63. Durán J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. *Am J Respir Crit Care Med* 2001;163:685–689.
 64. Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Rein J, Vela-Bueno A, et al. Prevalence of sleep-disordered breathing in women: effects of gender. *Am J Respir Crit Care Med* 2001;163:608–613.
 65. Kim J, In K, Kim J, You S, Kang K, Shim J, et al. Prevalence of sleep-disordered breathing in middle-aged Korean men and women. *Am J Respir Crit Care Med* 2004;170:1108–1113.
 66. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol* 2013;177:1006–1014.

67. Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. *Lancet Respir Med* 2015;3:310-318.
68. Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. *Sleep Med Rev* 2017;34:70-81.
69. Guilleminault C, Tilkian A, Dement WC. The sleep apnea syndromes. *Annu Rev Med* 1976;27:465-484.
70. Bassetti CL, Hermann DM. Sleep and stroke. *Handb Clin Neurol* 2011;99:1051-1072.
71. Sanfilippo-Cohn B, Lai S, Zhan G, Fenik P, Pratico D, Mazza E, et al. Sex differences in susceptibility to oxidative injury and sleepiness from intermittent hypoxia. *Sleep* 2006;29:152-159.
72. Veasey SC, Davis CW, Fenik P, Zhan G, Hsu YJ, Pratico D, et al. Long-term intermittent hypoxia in mice: protracted hypersomnolence with oxidative injury to sleep-wake brain regions. *Sleep* 2004;27:194-201.
73. Zhan G, Fenik P, Pratico D, Veasey SC. Inducible nitric oxide synthase in long-term intermittent hypoxia: hypersomnolence and brain injury. *Am J Respir Crit Care Med* 2005;171:1414-1420.
74. Morrell MJ. Residual sleepiness in patients with optimally treated sleep apnea: a case for hypoxia-induced oxidative brain injury. *Sleep* 2004;27:186-187.
75. Gozal E, Gozal D, Pierce WM, Thongboonkerd V, Scherzer JA, Sachleben LR Jr, et al. Proteomic analysis of CA1 and CA3 regions of rat hippocampus and differential susceptibility to intermittent hypoxia. *J Neurochem* 2002;83:331-345.
76. Hambrecht VS, Vlissides PE, Row BW, Gozal D, Baghdoyan HA, Lydic R. Hypoxia modulates cholinergic but not opioid activation of G proteins in rat hippocampus. *Hippocampus* 2007;17:934-942.
77. Row BW, Kheirandish L, Cheng Y, Rowell PP, Gozal D. Impaired spatial working memory and altered choline acetyltransferase (CHAT) immunoreactivity and nicotinic receptor binding in rats exposed to intermittent hypoxia during sleep. *Behav Brain Res* 2007;177:308-314.
78. Zhu Y, Fenik P, Zhan G, Mazza E, Kelz M, Aston-Jones G, et al. Selective loss of catecholaminergic wake active neurons in a murine sleep apnea model. *J Neurosci* 2007;27:10060-10071.
79. Row BW, Liu R, Xu W, Kheirandish L, Gozal D. Intermittent hypoxia is associated with oxidative stress and spatial learning deficits in the rat. *Am J Respir Crit Care Med* 2003;167:1548-1553.
80. Xu W, Chi L, Row BW, Xu R, Ke Y, Xu B, et al. Increased oxidative stress is associated with chronic intermittent hypoxia-mediated brain cortical neuronal cell apoptosis in a mouse model of sleep apnea. *Neuroscience* 2004;126:313-323.
81. Li RC, Row BW, Kheirandish L, Brittian KR, Gozal E, Guo SZ, et al. Nitric oxide synthase and intermittent hypoxia-induced spatial learning deficits in the rat. *Neurobiol Dis* 2004;17:44-53.
82. Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia: revisited. The bad ugly and good: implications to the heart and brain. *Sleep Med Rev* 2015;20:27-45.
83. Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Oda N, Tanaka A, et al. Silent brain infarction and platelet activation in obstructive sleep apnea. *Am J Respir Crit Care Med* 2007;175:612-617.
84. Kim H, Yun CH, Thomas RJ, Lee SH, Seo HS, Cho ER, et al. Obstructive sleep apnea as a risk factor for cerebral white matter change in a middle-aged and older general population. *Sleep* 2013;36:709B-715B.
85. Koo DL, Kim JY, Lim JS, Kwon HM, Nam H. Cerebral microbleeds on MRI in patients with obstructive sleep apnea. *J Clin Sleep Med* 2017;13:65-72.
86. Song TJ, Park JH, Choi KH, Chang Y, Moon J, Kim JH, et al. Moderate-to-severe obstructive sleep apnea is associated with cerebral small vessel disease. *Sleep Med* 2017;30:36-42.
87. Song TJ, Park JH, Choi KH, Kim JH, Choi Y, Chang Y, et al. Is obstructive sleep apnea associated with the presence of intracranial cerebral atherosclerosis? *Sleep Breath* 2017;21:639-646.
88. Yun CH, Jung KH, Chu K, Kim SH, Ji KH, Park HK, et al. Increased circulating endothelial microparticles and carotid atherosclerosis in obstructive sleep apnea. *J Clin Neurol* 2010;6:89-98.
89. Kim J, Mohler ER 3rd, Keenan BT, Maislin D, Arnardottir ES, Gislason T, et al. Carotid artery wall thickness in obese and non-obese adults with obstructive sleep apnea before and following positive airway pressure treatment. *Sleep* 2017;40:zsx126.
90. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. *JAMA* 2000;283:1829-1836.
91. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med* 2000;342:1378-1384.
92. Williams SK, Ravenell J, Jean-Louis G, Zizi F, Underberg JA, McFarlane SI, et al. Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management. *Curr Diab Rep* 2011;11:64-69.
93. Becker HF, Jerrentrup A, Ploch T, Grote L, Penzel T, Sullivan

- CE, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. *Circulation* 2003;107:68–73.
94. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. *Lancet* 2002;359:204–210.
 95. Martínez-García MA, Capote F, Campos-Rodríguez F, Lloberes P, Díaz de Atauri MJ, Somoza M, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. *JAMA* 2013;310:2407–2415.
 96. Rasche K, Keller T, Tautz B, Hader C, Hergenc G, Antosiewicz J, et al. Obstructive sleep apnea and type 2 diabetes. *Eur J Med Res* 2010;15 Suppl 2:152–156.
 97. Martínez-Cerón E, Barquiel B, Bezos AM, Casitas R, Galera R, García-Benito C, et al. Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes. a randomized clinical trial. *Am J Respir Crit Care Med* 2016;194:476–485.
 98. Mokhlesi B, Grimaldi D, Beccuti G, Abraham V, Whitmore H, Delebecque F, et al. Effect of one week of 8-hour nightly continuous positive airway pressure treatment of obstructive sleep apnea on glycemic control in type 2 diabetes: a proof-of-concept study. *Am J Respir Crit Care Med* 2016;194:516–519.
 99. Yamashita T, Murakawa Y, Sezaki K, Inoue M, Hayami N, Shuzui Y, et al. Circadian variation of paroxysmal atrial fibrillation. *Circulation* 1997;96:1537–1541.
 100. Mehra R, Benjamin EJ, Shahar E, Gottlieb DJ, Nawabit R, Kirchner HL, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: the Sleep Heart Health Study. *Am J Respir Crit Care Med* 2006;173:910–916.
 101. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. *J Am Coll Cardiol* 2007;49:565–571.
 102. Cadby G, McArdle N, Briffa T, Hillman DR, Simpson L, Knui-man M, et al. Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort. *Chest* 2015;148:945–952.
 103. Yazdan-Ashoori P, Baranchuk A. Obstructive sleep apnea may increase the risk of stroke in AF patients: refining the CHADS2 score. *Int J Cardiol* 2011;146:131–133.
 104. Szymanski FM, Filipiak KJ, Platek AE, Hryniewicz-Szymanska A, Karpinski G, Opolski G. Assessment of CHADS2 and CHA2DS2-VASc scores in obstructive sleep apnea patients with atrial fibrillation. *Sleep Breath* 2015;19:531–537.
 105. Guilleminault C, Connolly SJ, Winkle RA. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. *Am J Cardiol* 1983;52:490–494.
 106. Kanagala R, Murali NS, Friedman PA, Ammash NM, Gersh BJ, Ballman KV, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. *Circulation* 2003;107:2589–2594.
 107. McNicholas WT. Obstructive sleep apnea and inflammation. *Prog Cardiovasc Dis* 2009;51:392–399.
 108. Mehra R, Storer-Isser A, Kirchner HL, Johnson N, Jenny N, Tracy RP, et al. Soluble interleukin 6 receptor: a novel marker of moderate to severe sleep-related breathing disorder. *Arch Intern Med* 2006;166:1725–1731.
 109. Thomopoulos C, Tsioufis C, Dimitriadis K, Tsiachris D, Tousoulis D, Manolis A, et al. Obstructive sleep apnoea syndrome is associated with enhanced sub-clinical inflammation and asymmetric dimethyl-arginine levels in hypertensives. *J Hum Hypertens* 2009;23:65–67.
 110. Yue HJ, Mills PJ, Ancoli-Israel S, Loreda JS, Ziegler MG, Dimsdale JE. The roles of TNF-alpha and the soluble TNF receptor I on sleep architecture in OSA. *Sleep Breath* 2009;13:263–269.
 111. Lurie A. Endothelial dysfunction in adults with obstructive sleep apnea. *Adv Cardiol* 2011;46:139–170.
 112. Wang J, Yu W, Gao M, Zhang F, Gu C, Yu Y, et al. Impact of obstructive sleep apnea syndrome on endothelial function, arterial stiffening, and serum inflammatory markers: an updated meta-analysis and metaregression of 18 studies. *J Am Heart Assoc* 2015;4:e002454.
 113. Wessendorf TE, Thilman AF, Wang YM, Schreiber A, Konietzko N, Teschler H. Fibrinogen levels and obstructive sleep apnea in ischemic stroke. *Am J Respir Crit Care Med* 2000;162:2039–2042.
 114. von Känel R, Dimsdale JE. Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. *Chest* 2003;124:1956–1967.
 115. Saygin M, Ozturk O, Ozguner MF, Akkaya A, Varol E. Hematological parameters as predictors of cardiovascular disease in obstructive sleep apnea syndrome patients. *Angiology* 2016; 67:461–470.
 116. Diomedì M, Placidi F, Cupini LM, Bernardi G, Silvestrini M. Cerebral hemodynamic changes in sleep apnea syndrome and effect of continuous positive airway pressure treatment. *Neurology* 1998;51:1051–1056.
 117. Pizza F, Biallas M, Wolf M, Werth E, Bassetti CL. Nocturnal cerebral hemodynamics in snorers and in patients with obstructive sleep apnea: a near-infrared spectroscopy study. *Sleep* 2010;33:205–210.
 118. Prilipko O, Huynh N, Thomason ME, Kushida CA, Guilleminault C. An fMRI study of cerebrovascular reactivity and

- perfusion in obstructive sleep apnea patients before and after CPAP treatment. *Sleep Med* 2014;15:892–898.
119. Bassetti C, Aldrich MS, Chervin RD, Quint D. Sleep apnea in patients with transient ischemic attack and stroke: a prospective study of 59 patients. *Neurology* 1996;47:1167–1173.
 120. Parra O, Arboix A, Bechich S, García-Eroles L, Montserrat JM, López JA, et al. Time course of sleep-related breathing disorders in first-ever stroke or transient ischemic attack. *Am J Respir Crit Care Med* 2000;161:375–380.
 121. Turkington PM, Bamford J, Wanklyn P, Elliott MW. Prevalence and predictors of upper airway obstruction in the first 24 hours after acute stroke. *Stroke* 2002;33:2037–2042.
 122. Ahn SH, Kim JH, Kim DU, Choo IS, Lee HJ, Kim HW. Interaction between sleep-disordered breathing and acute ischemic stroke. *J Clin Neurol* 2013;9:9–13.
 123. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto FJ, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. *Am J Respir Crit Care Med* 2001;163:19–25.
 124. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. *Am J Respir Crit Care Med* 2002;166:159–165.
 125. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet* 2005;365:1046–1053.
 126. Munoz R, Duran-Cantolla J, Martínez-Vila E, Gallego J, Rubio R, Aizpuru F, et al. Severe sleep apnea and risk of ischemic stroke in the elderly. *Stroke* 2006;37:2317–2321.
 127. Young T, Finn L, Peppard PE, Szklo-Coxe M, Austin D, Nieto FJ, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. *Sleep* 2008;31:1071–1078.
 128. Yeboah J, Redline S, Johnson C, Tracy R, Ouyang P, Blumenthal RS, et al. Association between sleep apnea, snoring, incident cardiovascular events and all-cause mortality in an adult population: MESA. *Atherosclerosis* 2011;219:963–968.
 129. Redline S, Schluchter MD, Larkin EK, Tishler PV. Predictors of longitudinal change in sleep-disordered breathing in a non-clinic population. *Sleep* 2003;26:703–709.
 130. Dong JY, Zhang YH, Qin LQ. Obstructive sleep apnea and cardiovascular risk: meta-analysis of prospective cohort studies. *Atherosclerosis* 2013;229:489–495.
 131. Patrick AR, Shrank WH, Glynn RJ, Solomon DH, Dormuth CR, Avorn J, et al. The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. *Value Health* 2011;14:513–520.
 132. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. *BMJ* 2006;333:15.
 133. Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S; INCOSACT Initiative (International Collaboration of Sleep Apnea Cardiovascular Trialists). Sleep apnea and cardiovascular disease: lessons from recent trials and need for team science. *Circulation* 2017;136:1840–1850.
 134. Peker Y, Glantz H, Thunström E, Kallryd A, Herlitz J, Ejdebäck J. Rationale and design of the Randomized Intervention with CPAP in Coronary Artery Disease and Sleep Apnoea: RICCAD-SA trial. *Scand Cardiovasc J* 2009;43:24–31.
 135. Antic NA, Heeley E, Anderson CS, Luo Y, Wang J, Neal B, et al. The Sleep Apnea cardiovascular Endpoints (SAVE) Trial: rationale, ethics, design, and progress. *Sleep* 2015;38:1247–1257.
 136. Mokhlesi B, Ayas NT. Cardiovascular events in obstructive sleep apnea: can CPAP therapy SAVE lives? *N Engl J Med* 2016;375:994–996.
 137. Parthasarathy S. The positive and negative about positive airway pressure therapy. *Am J Respir Crit Care Med* 2016;194:535–537.
 138. Li Y, Vgontzas AN, Fernandez-Mendoza J, Kritikou I, Basta M, Pejovic S, et al. Objective, but not subjective, sleepiness is associated with inflammation in sleep apnea. *Sleep* 2017;40:zsw033.
 139. Barceló A, Barbé F, de la Peña M, Martínez P, Soriano JB, Piérola J, et al. Insulin resistance and daytime sleepiness in patients with sleep apnoea. *Thorax* 2008;63:946–950.
 140. Robinson GV, Langford BA, Smith DM, Stradling JR. Predictors of blood pressure fall with continuous positive airway pressure (CPAP) treatment of obstructive sleep apnoea (OSA). *Thorax* 2008;63:855–859.
 141. Barbé F, Mayorals LR, Duran J, Masa JF, Maimó A, Montserrat JM, et al. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial. *Ann Intern Med* 2001;134:1015–1023.
 142. Robinson GV, Smith DM, Langford BA, Davies RJ, Stradling JR. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. *Eur Respir J* 2006;27:1229–1235.
 143. Craig SE, Kohler M, Nicoll D, Bratton DJ, Nunn A, Davies R, et al. Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. *Thorax* 2012;67:1090–1096.
 144. Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, Martínez-

- Alonso M, Carmona C, Barceló A, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. *JAMA* 2012;307:2161–2168.
145. Bratton DJ, Stradling JR, Barbé F, Kohler M. Effect of CPAP on blood pressure in patients with minimally symptomatic obstructive sleep apnoea: a meta-analysis using individual patient data from four randomised controlled trials. *Thorax* 2014;69:1128–1135.
 146. Campos-Rodriguez F, Peña-Griñan N, Reyes-Nuñez N, De la Cruz-Moron I, Perez-Ronchel J, De la Vega-Gallardo F, et al. Mortality in obstructive sleep apnea-hypopnea patients treated with positive airway pressure. *Chest* 2005;128:624–633.
 147. Barbé F, Durán-Cantolla J, Capote F, de la Peña M, Chiner E, Masa JF, et al. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. *Am J Respir Crit Care Med* 2010;181:718–726.
 148. Bianchi MT, Alameddine Y, Mojica J. Apnea burden: efficacy versus effectiveness in patients using positive airway pressure. *Sleep Med* 2014;15:1579–1581.
 149. Boyd SB, Upender R, Walters AS, Goodpaster RL, Stanley JJ, Wang L, et al. Effective apnea-hypopnea index (“Effective AHI”): a new measure of effectiveness for positive airway pressure therapy. *Sleep* 2016;39:1961–1972.
 150. Thomas RJ, Bianchi MT. Urgent need to improve PAP management: the devil is in two (fixable) details. *J Clin Sleep Med* 2017;13:657–664.
 151. Kohler M, Stoewhas AC, Ayers L, Senn O, Bloch KE, Russi EW, et al. Effects of continuous positive airway pressure therapy withdrawal in patients with obstructive sleep apnea: a randomized controlled trial. *Am J Respir Crit Care Med* 2011;184:1192–1199.
 152. Young LR, Taxin ZH, Norman RG, Walsleben JA, Rapoport DM, Ayappa I. Response to CPAP withdrawal in patients with mild versus severe obstructive sleep apnea/hypopnea syndrome. *Sleep* 2013;36:405–412.
 153. Mokhlesi B, Finn LA, Hagen EW, Young T, Hla KM, Van Cauter E, et al. Obstructive sleep apnea during REM sleep and hypertension. Results of the Wisconsin Sleep Cohort. *Am J Respir Crit Care Med* 2014;190:1158–1167.
 154. Appleton SL, Vakulin A, Martin SA, Lang CJ, Wittert GA, Taylor AW, et al. Hypertension is associated with undiagnosed OSA during rapid eye movement sleep. *Chest* 2016;150:495–505.
 155. Mokhlesi B, Hagen EW, Finn LA, Hla KM, Carter JR, Peppard PE. Obstructive sleep apnoea during REM sleep and incident non-dipping of nocturnal blood pressure: a longitudinal analysis of the Wisconsin Sleep Cohort. *Thorax* 2015;70:1062–1069.
 156. Chami HA, Gottlieb DJ, Redline S, Punjabi NM. Association between glucose metabolism and sleep-disordered breathing during REM sleep. *Am J Respir Crit Care Med* 2015;192:1118–1126.
 157. Aurora RN, Crainiceanu C, Gottlieb DJ, Kim JS, Punjabi NM. Obstructive sleep apnea during rapid eye movement sleep and cardiovascular disease. *Am J Respir Crit Care Med*. 2017 Nov 7 [Epub]. <https://doi.org/10.1164/rccm.201706-11120C>.
 158. Mokhlesi B, Varga AW. Obstructive sleep apnea and cardiovascular disease: REM sleep matters! *Am J Respir Crit Care Med*. 2017 Nov 15 [Epub]. <https://doi.org/10.1164/rccm.201710-2147ED>.
 159. Collop NA, Tracy SL, Kapur V, Mehra R, Kuhlmann D, Fleishman SA, et al. Obstructive sleep apnea devices for out-of-center (OOC) testing: technology evaluation. *J Clin Sleep Med* 2011;7:531–548.
 160. Malhotra A, Patil S, Sands S, Ayas N. Central sleep apnoea in congestive heart failure. *Lancet Respir Med* 2015;3:507–508.
 161. Magalang UJ, Pack AI. Heart failure and sleep-disordered breathing: the plot thickens. *N Engl J Med* 2015;373:1166–1167.
 162. Boulos MI, Murray BJ, Muir RT, Gao F, Szilagyi GM, Huroy M, et al. Periodic limb movements and white matter hyperintensities in first-ever minor stroke or high-risk transient ischemic attack. *Sleep* 2017;40:zsw080.
 163. Katsanos AH, Kosmidou M, Konitsiotis S, Tsvigoulis G, Fiolaki A, Kyritsis AP, et al. Restless legs syndrome and cerebrovascular/cardiovascular events: systematic review and meta-analysis. *Acta Neurol Scand* 2018;137:142–148.
 164. Kendzerska T, Kamra M, Murray BJ, Boulos MI. Incident cardiovascular events and death in individuals with restless legs syndrome or periodic limb movements in sleep: a systematic review. *Sleep* 2017;40:zsx013.
 165. Eckert DJ. Phenotypic approaches to obstructive sleep apnoea: new pathways for targeted therapy. *Sleep Med Rev* 2018;37:45–59.
 166. Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. *J Am Coll Cardiol* 2017;69:841–858.
 167. Zinchuk AV, Gentry MJ, Concato J, Yaggi HK. Phenotypes in obstructive sleep apnea: a definition, examples and evolution of approaches. *Sleep Med Rev* 2017;35:113–123.
 168. Edwards BA, Sands SA, Eckert DJ, White DP, Butler JP, Owens RL, et al. Acetazolamide improves loop gain but not the other physiological traits causing obstructive sleep apnoea. *J Physiol* 2012;590:1199–1211.

169. Thomas RJ. Alternative approaches to treatment of Central Sleep Apnea. *Sleep Med Clin* 2014;9:87–104.
170. Reiter J, Zleik B, Bazalakova M, Mehta P, Thomas RJ. Residual events during use of CPAP: prevalence, predictors, and detection accuracy. *J Clin Sleep Med* 2016;12:1153–1158.
171. Campos-Rodriguez F, Martinez-Garcia MA, Reyes-Nuñez N, Caballero-Martinez I, Catalan-Serra P, Almeida-Gonzalez CV. Role of sleep apnea and continuous positive airway pressure therapy in the incidence of stroke or coronary heart disease in women. *Am J Respir Crit Care Med* 2014;189:1544–1550.
172. Chen JC, Brunner RL, Ren H, Wassertheil-Smoller S, Larson JC, Levine DW, et al. Sleep duration and risk of ischemic stroke in postmenopausal women. *Stroke* 2008;39:3185–3192.
173. Helbig AK, Stöckl D, Heier M, Ladwig KH, Meisinger C. Symptoms of insomnia and sleep duration and their association with incident strokes: findings from the population-based MONICA/KORA Augsburg Cohort Study. *PLoS One* 2015;10:e0134480.
174. von Ruesten A, Weikert C, Fietze I, Boeing H. Association of sleep duration with chronic diseases in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. *PLoS One* 2012;7:e30972.
175. Li W, Wang D, Cao S, Yin X, Gong Y, Gan Y, et al. Sleep duration and risk of stroke events and stroke mortality: a systematic review and meta-analysis of prospective cohort studies. *Int J Cardiol* 2016;223:870–876.
176. Gangwisch JE, Heymsfield SB, Boden-Albala B, Buijs RM, Kreier F, Pickering TG, et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. *Hypertension* 2006;47:833–839.
177. Gangwisch JE, Malaspina D, Babiss LA, Opler MG, Posner K, Shen S, et al. Short sleep duration as a risk factor for hypercholesterolemia: analyses of the National Longitudinal Study of Adolescent Health. *Sleep* 2010;33:956–961.
178. Pan A, De Silva DA, Yuan JM, Koh WP. Sleep duration and risk of stroke mortality among Chinese adults: Singapore Chinese health study. *Stroke* 2014;45:1620–1625.
179. Kim Y, Wilkens LR, Schembre SM, Henderson BE, Kolonel LN, Goodman MT. Insufficient and excessive amounts of sleep increase the risk of premature death from cardiovascular and other diseases: the Multiethnic Cohort Study. *Prev Med* 2013;57:377–385.
180. Chaput JP, Després JP, Bouchard C, Astrup A, Tremblay A. Sleep duration as a risk factor for the development of type 2 diabetes or impaired glucose tolerance: analyses of the Quebec Family Study. *Sleep Med* 2009;10:919–924.
181. Kawachi T, Wada K, Nakamura K, Tsuji M, Tamura T, Konishi K, et al. Sleep duration and the risk of mortality from stroke in Japan: the Takayama Cohort Study. *J Epidemiol* 2016; 26:123–130.
182. Qureshi AI, Giles WH, Croft JB, Bliwise DL. Habitual sleep patterns and risk for stroke and coronary heart disease: a 10-year follow-up from NHANES I. *Neurology* 1997;48:904–911.
183. Cai H, Shu XO, Xiang YB, Yang G, Li H, Ji BT, et al. Sleep duration and mortality: a prospective study of 113 138 middle-aged and elderly Chinese men and women. *Sleep* 2015; 38:529–536.
184. Ge B, Guo X. Short and long sleep durations are both associated with increased risk of stroke: a meta-analysis of observational studies. *Int J Stroke* 2015;10:177–184.
185. Lockley SW, Skene DJ, Arendt J. Comparison between subjective and actigraphic measurement of sleep and sleep rhythms. *J Sleep Res* 1999;8:175–183.
186. Signal TL, Gale J, Gander PH. Sleep measurement in flight crew: comparing actigraphic and subjective estimates to polysomnography. *Aviat Space Environ Med* 2005;76:1058–1063.
187. Lauderdale DS, Knutson KL, Yan LL, Liu K, Rathouz PJ. Self-reported and measured sleep duration: how similar are they? *Epidemiology* 2008;19:838–845.
188. Li AM, Lam HS, Chan MH, So HK, Ng SK, Chan IH, et al. Inflammatory cytokines and childhood obstructive sleep apnoea. *Ann Acad Med Singapore* 2008;37:649–654.
189. Gallicchio L, Kalesan B. Sleep duration and mortality: a systematic review and meta-analysis. *J Sleep Res* 2009;18:148–158.
190. Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler MR. Mortality associated with sleep duration and insomnia. *Arch Gen Psychiatry* 2002;59:131–136.
191. Patel SR, Malhotra A, Gottlieb DJ, White DP, Hu FB. Correlates of long sleep duration. *Sleep* 2006;29:881–889.
192. Ferrie JE, Shipley MJ, Cappuccio FP, Brunner E, Miller MA, Kumari M, et al. A prospective study of change in sleep duration: associations with mortality in the Whitehall II cohort. *Sleep* 2007;30:1659–1666.
193. Taheri S, Lin L, Austin D, Young T, Mignot E. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. *PLoS Med* 2004;1:e62.
194. Knutson KL, Spiegel K, Penev P, Van Cauter E. The metabolic consequences of sleep deprivation. *Sleep Med Rev* 2007;11:163–178.
195. Schmid SM, Hallschmid M, Jauch-Chara K, Wilms B, Benedict C, Lehnert H, et al. Short-term sleep loss decreases physical activity under free-living conditions but does not increase food intake under time-deprived laboratory conditions in healthy men. *Am J Clin Nutr* 2009;90:1476–1482.
196. Vaara J, Kyröläinen H, Koivu M, Tulppo M, Finni T. The effect

- of 60-h sleep deprivation on cardiovascular regulation and body temperature. *Eur J Appl Physiol* 2009;105:439-444.
197. Phua CS, Jayaram L, Wijeratne T. Relationship between sleep duration and risk factors for stroke. *Front Neurol* 2017;8:392.
 198. González-Ortiz M, Martínez-Abundis E, Balcázar-Muñoz BR, Pascoe-González S. Effect of sleep deprivation on insulin sensitivity and cortisol concentration in healthy subjects. *Diabetes Nutr Metab* 2000;13:80-83.
 199. Covassin N, Bukartyk J, Sahakyan K, Svatikova A, Calvin A, St Louis EK, et al. Experimental sleep restriction increases nocturnal blood pressure and attenuates blood pressure dipping in healthy individuals. *J Am Coll Cardiol* 2015;65(10 Suppl):A1352.
 200. Knutson KL, Van Cauter E, Rathouz PJ, Yan LL, Hulley SB, Liu K, et al. Association between sleep and blood pressure in midlife: the CARDIA sleep study. *Arch Intern Med* 2009;169:1055-1061.
 201. Kim JY, Yadav D, Ahn SV, Koh SB, Park JT, Yoon J, et al. A prospective study of total sleep duration and incident metabolic syndrome: the ARIRANG study. *Sleep Med* 2015;16:1511-1515.
 202. Zhan Y, Chen R, Yu J. Sleep duration and abnormal serum lipids: the China Health and Nutrition Survey. *Sleep Med* 2014;15:833-839.
 203. Meier-Ewert HK, Ridker PM, Rifai N, Regan MM, Price NJ, Dinges DF, et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. *J Am Coll Cardiol* 2004;43:678-683.
 204. Shearer WT, Reuben JM, Mullington JM, Price NJ, Lee BN, Smith EO, et al. Soluble TNF- α receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. *J Allergy Clin Immunol* 2001;107:165-170.
 205. Prather AA, Vogelzangs N, Penninx BW. Sleep duration, insomnia, and markers of systemic inflammation: results from the Netherlands Study of Depression and Anxiety (NESDA). *J Psychiatr Res* 2015;60:95-102.
 206. Abe T, Aoki T, Yata S, Okada M. Sleep duration is significantly associated with carotid artery atherosclerosis incidence in a Japanese population. *Atherosclerosis* 2011;217:509-513.
 207. Khawaja O, Sarwar A, Albert CM, Gaziano JM, Djoussé L. Sleep duration and risk of atrial fibrillation (from the Physicians' Health Study). *Am J Cardiol* 2013;111:547-551.
 208. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 1991;22:983-988.
 209. Ramos AR, Dong C, Rundek T, Elkind MS, Boden-Albala B, Sacco RL, et al. Sleep duration is associated with white matter hyperintensity volume in older adults: the Northern Manhattan Study. *J Sleep Res* 2014;23:524-530.
 210. Ramos AR, Gangwisch JE. Is sleep duration a risk factor for stroke? *Neurology* 2015;84:1066-1067.
 211. Knutson KL, Turek FW. The U-shaped association between sleep and health: the 2 peaks do not mean the same thing. *Sleep* 2006;29:878-879.
 212. Grandner MA, Drummond SP. Who are the long sleepers? Towards an understanding of the mortality relationship. *Sleep Med Rev* 2007;11:341-360.
 213. Hwangbo Y, Kim WJ, Chu MK, Yun CH, Yang KI. Association between weekend catch-up sleep duration and hypertension in Korean adults. *Sleep Med* 2013;14:549-554.
 214. Im HJ, Baek SH, Chu MK, Yang KI, Kim WJ, Park SH, et al. Association between weekend catch-up sleep and lower body mass: population-based study. *Sleep* 2017;40:zsx089.
 215. Buysse DJ. Insomnia. *JAMA* 2013;309:706-716.
 216. American Academy of Sleep Medicine. The International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine, 2014.
 217. Chien KL, Chen PC, Hsu HC, Su TC, Sung FC, Chen MF, et al. Habitual sleep duration and insomnia and the risk of cardiovascular events and all-cause death: report from a community-based cohort. *Sleep* 2010;33:177-184.
 218. Bonnet MH, Arand DL. Cardiovascular implications of poor sleep. *Sleep Med Clin* 2007;2:529-538.
 219. Phillips B, Mannino DM. Do insomnia complaints cause hypertension or cardiovascular disease? *J Clin Sleep Med* 2007;3:489-494.
 220. Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. *Sleep* 2009;32:491-497.
 221. Fernandez-Mendoza J, Calhoun S, Bixler EO, Pejovic S, Karata-raki M, Liao D, et al. Insomnia with objective short sleep duration is associated with deficits in neuropsychological performance: a general population study. *Sleep* 2010;33:459-465.
 222. Fernandez-Mendoza J, Vgontzas AN, Liao D, Shaffer ML, Vela-Bueno A, Basta M, et al. Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort. *Hypertension* 2012;60:929-935.
 223. Scofield H, Roth T, Drake C. Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differences. *Sleep* 2008;31:1221-1227.
 224. Hornyak M, Feige B, Riemann D, Voderholzer U. Periodic leg movements in sleep and periodic limb movement disorder: prevalence, clinical significance and treatment. *Sleep Med Rev* 2006;10:169-177.
 225. Kendzerska T, Gershon AS, Hawker G, Leung RS, Tomlinson G. Obstructive sleep apnea and risk of cardiovascular events and all-cause mortality: a decade-long historical cohort study. *PLoS Med* 2014;11:e1001599.
 226. Mirza M, Shen WK, Sofi A, Jahangir A, Mori N, Tajik AJ, et al.

- Frequent periodic leg movement during sleep is associated with left ventricular hypertrophy and adverse cardiovascular outcomes. *J Am Soc Echocardiogr* 2013;26:783-790.
227. Walters AS, Rye DB. Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke. *Sleep* 2009;32:589-597.
228. Pennestri MH, Montplaisir J, Colombo R, Lavigne G, Lanfranchi PA. Nocturnal blood pressure changes in patients with restless legs syndrome. *Neurology* 2007;68:1213-1218.
229. Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria. History, rationale, description, and significance. *Sleep Med* 2014;15:860-873.
230. Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. *Neurology* 2008;70:35-42.
231. Elwood P, Hack M, Pickering J, Hughes J, Gallacher J. Sleep disturbance, stroke, and heart disease events: evidence from the Caerphilly cohort. *J Epidemiol Community Health* 2006;60:69-73.
232. Molnar MZ, Lu JL, Kalantar-Zadeh K, Kovesdy CP. Association of incident restless legs syndrome with outcomes in a large cohort of US veterans. *J Sleep Res* 2016;25:47-56.
233. Szentkirályi A, Völzke H, Hoffmann W, Happe S, Berger K. A time sequence analysis of the relationship between cardiovascular risk factors, vascular diseases and restless legs syndrome in the general population. *J Sleep Res* 2013;22:434-442.
234. Winter AC, Berger K, Glynn RJ, Buring JE, Gaziano JM, Schürks M, et al. Vascular risk factors, cardiovascular disease, and restless legs syndrome in men. *Am J Med* 2013;126:228-235.
235. Li Y, Li Y, Winkelman JW, Walters AS, Han J, Hu FB, et al. Prospective study of restless legs syndrome and total and cardiovascular mortality among women. *Neurology* 2018;90:e135-e141.
236. Li Y, Wang W, Winkelman JW, Malhotra A, Ma J, Gao X. Prospective study of restless legs syndrome and mortality among men. *Neurology* 2013;81:52-59.
237. Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. *Sleep Med* 2006;7:545-552.
238. Schilling C, Schredl M, Strobl P, Deuschle M. Restless legs syndrome: evidence for nocturnal hypothalamic-pituitary-adrenal system activation. *Mov Disord* 2010;25:1047-1052.
239. May AM, Blackwell T, Stone KL, Cawthon PM, Sauer WH, Varosy PD, et al. Longitudinal relationships of periodic limb movements during sleep and incident atrial fibrillation. *Sleep Med* 2016;25:78-86.
240. Hannerz H, Albertsen K, Nielsen ML, Tuchsén F, Burr H. Occupational factors and 5-year weight change among men in a danish national cohort. *Health Psychol* 2004;23:283-288.
241. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Speizer FE, et al. Prospective study of shift work and risk of coronary heart disease in women. *Circulation* 1995;92:3178-3182.
242. Suwazono Y, Dochi M, Oishi M, Tanaka K, Kobayashi E, Sakata K. Shiftwork and impaired glucose metabolism: a 14-year cohort study on 7104 male workers. *Chronobiol Int* 2009;26:926-941.
243. Suwazono Y, Dochi M, Sakata K, Okubo Y, Oishi M, Tanaka K, et al. A longitudinal study on the effect of shift work on weight gain in male Japanese workers. *Obesity (Silver Spring)* 2008;16:1887-1893.
244. Kecklund G, Axelsson J. Health consequences of shift work and insufficient sleep. *BMJ* 2016;355:i5210.